Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

ONTX was devalued by Zacks  from a “purchase” ranking to a “hold” ranking in a research note released to capitalists on Thursday, reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on discovering and also creating tiny particle drug prospects to deal with cancer. The Company‘s items under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research experts additionally lately talked about the business. Noble Financial reissued a “purchase” rating as well as released a $11.00 rate purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating typical cost of $2.90 as well as a two-hundred day relocating ordinary rate of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, topping analysts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an adverse web margin of 8,294.27%. The company had revenue of $0.06 million throughout the quarter, compared to the consensus estimate of $0.06 million. During the exact same quarter in the prior year, the company uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A number of hedge funds have lately dealt shares of ONTX. GSA Capital Allies LLP got a new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Administration LP bought a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a brand-new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also other institutional capitalists possess 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the recognition as well as growth of oncology therapeutics. It focuses on discovering and also developing small molecule drug candidates to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more concerning research offerings from Zacks Investment Research, see

This immediate information alert was generated by narrative science innovation and also economic information from Market in order to provide viewers with the fastest as well as most accurate reporting. This tale was evaluated by Market’s content team prior to publication. 



Prior to you think about Onconova Therapeutics, you’ll want to hear this.

Market tracks Wall Street’s top-rated and finest carrying out research experts as well as the stocks they suggest to their clients each day. Market has identified the 5 stocks that top experts are quietly murmuring to their clients to acquire now prior to the broader market catches on … and Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” score among analysts, premier experts believe these 5 stocks are better purchases.

Comments Off on Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research